MX2009010405A - Composicion en vesicula de lipido bifasico y metodo para tratar la displasia cervical mediante suministro intravaginal. - Google Patents
Composicion en vesicula de lipido bifasico y metodo para tratar la displasia cervical mediante suministro intravaginal.Info
- Publication number
- MX2009010405A MX2009010405A MX2009010405A MX2009010405A MX2009010405A MX 2009010405 A MX2009010405 A MX 2009010405A MX 2009010405 A MX2009010405 A MX 2009010405A MX 2009010405 A MX2009010405 A MX 2009010405A MX 2009010405 A MX2009010405 A MX 2009010405A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- treating cervical
- intravaginal delivery
- interferon alpha
- vesicle composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 230000002051 biphasic effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 206010008263 Cervical dysplasia Diseases 0.000 title 1
- 102100040018 Interferon alpha-2 Human genes 0.000 abstract 3
- 108010079944 Interferon-alpha2b Proteins 0.000 abstract 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 abstract 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 2
- 229930195722 L-methionine Natural products 0.000 abstract 2
- 229960004452 methionine Drugs 0.000 abstract 2
- 239000000232 Lipid Bilayer Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000007764 o/w emulsion Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90932407P | 2007-03-30 | 2007-03-30 | |
| PCT/CA2008/000563 WO2008119160A1 (en) | 2007-03-30 | 2008-03-27 | Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009010405A true MX2009010405A (es) | 2010-02-03 |
Family
ID=39807744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009010405A MX2009010405A (es) | 2007-03-30 | 2008-03-27 | Composicion en vesicula de lipido bifasico y metodo para tratar la displasia cervical mediante suministro intravaginal. |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8945529B2 (OSRAM) |
| EP (1) | EP2134353B1 (OSRAM) |
| JP (1) | JP5587762B2 (OSRAM) |
| KR (1) | KR20090130081A (OSRAM) |
| AU (1) | AU2008234364B2 (OSRAM) |
| CA (1) | CA2681565C (OSRAM) |
| CY (1) | CY1118794T1 (OSRAM) |
| DK (1) | DK2134353T3 (OSRAM) |
| ES (1) | ES2617063T3 (OSRAM) |
| HR (1) | HRP20170250T1 (OSRAM) |
| HU (1) | HUE033256T2 (OSRAM) |
| LT (1) | LT2134353T (OSRAM) |
| MX (1) | MX2009010405A (OSRAM) |
| PL (1) | PL2134353T3 (OSRAM) |
| PT (1) | PT2134353T (OSRAM) |
| SI (1) | SI2134353T1 (OSRAM) |
| TW (1) | TWI440477B (OSRAM) |
| WO (1) | WO2008119160A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3008900B1 (fr) * | 2013-07-25 | 2018-03-30 | Centre Nat Rech Scient | Nanoparticules lipidiques multicompartimentees |
| US8986732B2 (en) * | 2013-08-12 | 2015-03-24 | Helix Biopharma Corporation | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery |
| US10159646B2 (en) * | 2013-08-12 | 2018-12-25 | Altum-Avro Pharma Partnership | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US20150147382A1 (en) * | 2013-09-23 | 2015-05-28 | Exir Nano Sina Company | Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same |
| EP3625345B1 (en) | 2017-05-18 | 2023-05-24 | ModernaTX, Inc. | Modified messenger rna comprising functional rna elements |
| EP3630067A4 (en) * | 2017-05-26 | 2021-08-11 | Altum Pharmaceuticals Inc. | BIPHASIC CANNABINOID ADMINISTRATION |
| JP7423521B2 (ja) | 2017-11-22 | 2024-01-29 | モダーナティエックス・インコーポレイテッド | フェニルケトン尿症の治療用のフェニルアラニンヒドロキシラーゼをコードするポリヌクレオチド |
| EP3714048B1 (en) | 2017-11-22 | 2025-04-09 | ModernaTX, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
| MA53609A (fr) | 2018-09-13 | 2021-07-21 | Modernatx Inc | Polynucléotides codant la glucose-6-phosphatase pour le traitement de la glycogénose |
| AU2019339430A1 (en) | 2018-09-14 | 2021-04-29 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide A1 for the treatment of Crigler-Najjar Syndrome |
| BR112022005354A2 (pt) * | 2019-09-23 | 2022-08-23 | Dds Res Inc | Composições de vesícula lipídica com agentes potencializadores de penetração |
| US20240216288A1 (en) | 2021-03-24 | 2024-07-04 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof |
| WO2022204371A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
| WO2022204305A2 (en) | 2021-03-24 | 2022-09-29 | Glo Pharma, Inc. | Peptides and methods for reducing skin pigmentation |
| WO2022204390A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof |
| US20240376445A1 (en) | 2021-06-22 | 2024-11-14 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
| KR20240102989A (ko) * | 2021-11-04 | 2024-07-03 | 글로 파마, 인크. | 화장품 적용을 위한 방법 및 조성물 |
| TW202412818A (zh) | 2022-07-26 | 2024-04-01 | 美商現代公司 | 用於暫時控制表現之經工程化多核苷酸 |
| WO2024130158A1 (en) | 2022-12-16 | 2024-06-20 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5358708A (en) | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
| CA2168260C (en) | 1993-07-28 | 2000-04-11 | Marianna Foldvari | Biphasic multilamellar lipid vesicles |
| IN184589B (OSRAM) | 1996-10-16 | 2000-09-09 | Alza Corp | |
| US5993852A (en) * | 1997-08-29 | 1999-11-30 | Pharmaderm Laboratories Ltd. | Biphasic lipid vesicle composition for transdermal administration of an immunogen |
| US6656499B1 (en) * | 1999-11-12 | 2003-12-02 | Pharmaderm Laboratories, Ltd. | Composition for transdermal and dermal administration of interferon-α |
| TWI272948B (en) * | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
| EP1576952A1 (en) * | 2004-03-18 | 2005-09-21 | OctoPlus Technologies B.V. | Hydrogel microspheres with improved release profile |
-
2008
- 2008-03-27 ES ES08733666.5T patent/ES2617063T3/es active Active
- 2008-03-27 HU HUE08733666A patent/HUE033256T2/hu unknown
- 2008-03-27 SI SI200831765A patent/SI2134353T1/sl unknown
- 2008-03-27 WO PCT/CA2008/000563 patent/WO2008119160A1/en not_active Ceased
- 2008-03-27 US US12/532,752 patent/US8945529B2/en active Active
- 2008-03-27 LT LTEP08733666.5T patent/LT2134353T/lt unknown
- 2008-03-27 CA CA2681565A patent/CA2681565C/en active Active
- 2008-03-27 PL PL08733666T patent/PL2134353T3/pl unknown
- 2008-03-27 JP JP2010500036A patent/JP5587762B2/ja not_active Expired - Fee Related
- 2008-03-27 PT PT87336665T patent/PT2134353T/pt unknown
- 2008-03-27 MX MX2009010405A patent/MX2009010405A/es active IP Right Grant
- 2008-03-27 HR HRP20170250TT patent/HRP20170250T1/hr unknown
- 2008-03-27 EP EP08733666.5A patent/EP2134353B1/en active Active
- 2008-03-27 AU AU2008234364A patent/AU2008234364B2/en not_active Ceased
- 2008-03-27 KR KR1020097022186A patent/KR20090130081A/ko not_active Ceased
- 2008-03-27 DK DK08733666.5T patent/DK2134353T3/en active
- 2008-03-28 TW TW097111592A patent/TWI440477B/zh not_active IP Right Cessation
-
2013
- 2013-03-22 US US13/849,451 patent/US20130216610A1/en not_active Abandoned
- 2013-03-22 US US13/849,455 patent/US20130224283A1/en not_active Abandoned
-
2017
- 2017-02-14 CY CY20171100200T patent/CY1118794T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090130081A (ko) | 2009-12-17 |
| EP2134353A1 (en) | 2009-12-23 |
| CA2681565A1 (en) | 2008-10-09 |
| EP2134353B1 (en) | 2016-11-16 |
| ES2617063T3 (es) | 2017-06-15 |
| AU2008234364A1 (en) | 2008-10-09 |
| TW200846030A (en) | 2008-12-01 |
| CY1118794T1 (el) | 2017-07-12 |
| EP2134353A4 (en) | 2013-08-07 |
| WO2008119160A1 (en) | 2008-10-09 |
| US20130224283A1 (en) | 2013-08-29 |
| US8945529B2 (en) | 2015-02-03 |
| JP5587762B2 (ja) | 2014-09-10 |
| DK2134353T3 (en) | 2017-02-20 |
| TWI440477B (zh) | 2014-06-11 |
| AU2008234364B2 (en) | 2013-10-17 |
| PT2134353T (pt) | 2017-02-15 |
| JP2010522698A (ja) | 2010-07-08 |
| SI2134353T1 (sl) | 2017-03-31 |
| PL2134353T3 (pl) | 2017-06-30 |
| US20130216610A1 (en) | 2013-08-22 |
| LT2134353T (lt) | 2017-03-27 |
| HRP20170250T1 (hr) | 2017-04-07 |
| HUE033256T2 (hu) | 2017-11-28 |
| CA2681565C (en) | 2016-10-25 |
| US20100196453A1 (en) | 2010-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009010405A (es) | Composicion en vesicula de lipido bifasico y metodo para tratar la displasia cervical mediante suministro intravaginal. | |
| JP2010522698A5 (OSRAM) | ||
| EP0735859B1 (en) | A pharmaceutical composition for the intranasal administration of hydroxocobalamin | |
| Patton | Pulmonary delivery of drugs for bone disorders | |
| AP387A (en) | Therapeutical uses of L-methionine and compositions thereof. | |
| MX2009002314A (es) | Composiciones farmaceuticas que comprenden hgh para suministro oral. | |
| PL364174A1 (en) | Fibrate-statin combinations with reduced fed-fasted effects | |
| ATE522211T1 (de) | Stabilisierte fibrat-mikropartikel | |
| TW200501983A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
| De Lange et al. | Limited regression of central giant cell granuloma by interferon alpha after failed calcitonin therapy: a report of 2 cases | |
| KR19980702443A (ko) | 아데노신 결핍증의 치료방법 | |
| JP2009507838A5 (OSRAM) | ||
| NZ606383A (en) | Methods of treating pulmonary disorders with liposomal amikacin formulations | |
| CN101674843A (zh) | 多肽的经粘膜递送组合物 | |
| MA28004A1 (fr) | Traitement du sevrage de la dependance | |
| ZA201106419B (en) | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid | |
| HU229613B1 (en) | Oral administration of parathyroid hormone and calcitonin | |
| MX9706689A (es) | Tratamiento de trastornos causados por el factor de crecimiento de citocina. | |
| JOP20190019A1 (ar) | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) | |
| US5925625A (en) | Pharmaceutical composition for the intranasal administration of hydroxocobalamin | |
| JOP20170044B1 (ar) | تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو | |
| TW200517119A (en) | Method of treatment using interferon-tau | |
| CA2492378A1 (en) | Modified amino acid for the inhibition of platelet aggregation | |
| IL194346A0 (en) | Peptide substance stimulating regeneration of central nervous system neurons, pharmaceutical composition on its base, and the method of its application | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |